Chemotherapy Clinical Trials in Beijing

9 recruitingBeijing, China

Showing 19 of 9 trials

Recruiting
Phase 3

Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy

Peripheral Neuropathy Due to ChemotherapyPeripheral Neuropathy, Chemotherapy-induced
Qinghai Red Cross Hospital326 enrolled4 locationsNCT07423390
Recruiting
Phase 2

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)+2 more
AstraZeneca257 enrolled59 locationsNCT06535607
Recruiting
Phase 3

Neoadjuvant Treatment Modalities in Esophageal Cancer

Esophageal CancerSurgeryChemotherapy Effect+4 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences2,000 enrolled1 locationNCT04821843
Recruiting
Phase 3

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Esophagus CancerChemotherapy EffectTargeted Therapy+3 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences2,000 enrolled5 locationsNCT04821778
Recruiting
Phase 3

GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer

Chemotherapy-induced Peripheral Neuropathy (CIPN)
Qilu Pharmaceutical Co., Ltd.352 enrolled1 locationNCT06994507
Recruiting

Quantitative Nodal Burden as a Determinant Identifying Ampullary Adenocarcinoma Patients Benefiting From Adjuvant Chemotherapy

Chemotherapy EffectAmpullary Adenoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences300 enrolled1 locationNCT06435767
Recruiting
Phase 2

Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients

Esophageal CancerChemotherapyImmunotherapy+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences55 enrolled1 locationNCT06429839
Recruiting
Phase 2

Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

Esophageal CancerChemotherapyImmunotherapy+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences53 enrolled1 locationNCT06410651
Recruiting
Not Applicable

COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research

Lung CancerChemotherapyImmune Checkpoint Inhibitor+3 more
Peking Union Medical College Hospital1,224 enrolled1 locationNCT06168032